Spondyloarthritis & psoriatic arthritis
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
Authors' conclusion
The prevalence of clinically diagnosed PsA in adults, aged 18 to 79 years, in Sweden in 2017 was around 0.35%. Among PsA cases in recent contact with specialized rheumatology care, almost three-fourths received DMARD therapy in 2017.
Study context
- Population
- Individuals aged 18 to 79 years, alive and residing in Sweden on December 31, 2017, with a prior psoriatic arthritis (PsA) diagnosis in the National Patient Register (NPR) and/or SRQ
- Outcome
- Prevalence of clinically diagnosed PsA (base case definition)
- Follow-up
- 2017
Methodological detailsnational registers, NPR and/or SRQ
- National registers
- NPR and/or SRQ
Main finding
As reported in the abstract
Base case (BC) definition
0.39%
After accounting for diagnostic misclassification
0.34%
Across all sensitivity analyses
0.32% to 0.50%
Observational data: associations, not effects.
Further findings
Prevalence by sex and education · 2017
- Prevalence lower in males and in those with a higher level of education
Prevalence among those seen in specialized rheumatology care 2015–2017
- Prevalence
- 0.24%
Disease-modifying antirheumatic drug (DMARD) use in 2017 among those seen in specialized rheumatology care
- b/tsDMARD
- 32%
- csDMARD only
- 41%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →